Oncotarget

Research Papers: Pathology:

Increased circulating full-length betatrophin levels in drug-naïve metabolic syndrome

Dan Liu, Sheyu Li, He He, Chuan Yu, Xiaodan Li, Libo Liang, Yi Chen, Jianwei Li, Jianshu Li, Xin Sun, Haoming Tian and Zhenmei An _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:17510-17517. https://doi.org/10.18632/oncotarget.15102

Metrics: PDF 1309 views  |   HTML 1557 views  |   ?  


Abstract

Dan Liu1,*, Sheyu Li1,*, He He2,*, Chuan Yu3, Xiaodan Li4, Libo Liang5, Yi Chen6, Jianwei Li1, Jianshu Li7, Xin Sun3, Haoming Tian1 and Zhenmei An1

1 Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China

2 Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China

3 Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

4 Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

5 Department of General Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China

6 Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China

7 Department of Biomedical Polymer and Artificial Organs, College of Polymer Science and Engineering, Sichuan University, Chengdu, Sichuan, China

* These authors have contributed equally to this work

Correspondence to:

Zhenmei An, email:

Keywords: betatrophin, lipasin, ANGPTL8, metabolic syndrome, Pathology Section

Received: July 22, 2016 Accepted: January 23, 2017 Published: February 04, 2017

Abstract

Betatrophin is a newly identified circulating adipokine playing a role in the regulation of glucose homeostasis and lipid metabolism. But its role in metabolic syndrome (MetS) remains unknown. Therefore, we aimed to compare the circulating betatrophin concentrations between patients with MetS and healthy controls. We recruited 47 patients with MetS and 47 age and sex matched healthy controls. Anthropometric and biochemical measurements were performed, and serum betatrophin levels were detected by ELISA. Full-length betatrophin levels in patients with MetS were significantly higher than those in controls (694.84 ± 365.51 pg/ml versus 356.64 ± 287.92 pg/ml; P <0.001). While no significant difference of total betatrophin levels was found between the two groups (1.20 ± 0.79 ng/ml versus 1.31 ± 1.08 ng/ml; P = 0.524). Full-length betatrophin level was positively correlated with fasting plasma glucose (FPG) (r = 0.357, P = 0.014) and 2-hour plasma glucose (2hPG) (r = 0.38, P <0.01). Binary logistic regression models indicated that subjects in the tertile of the highest full-length betatrophin level experienced higher odds of having MetS (OR, 8.6; 95% CI 2.8-26.8; P <0.001). Our study showed that full-length betatrophin concentrations were increased in drug-naïve MetS patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15102